Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc.verified

ONCT

Price:

$7

Market Cap:

$20.72M

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen r...[Read more]

Industry

Biotechnology

IPO Date

2004-02-03

Stock Exchange

NASDAQ

Ticker

ONCT

The PE Ratio as of July 2024 (TTM) for Oncternal Therapeutics, Inc. (ONCT) is -0.57

According to Oncternal Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.57. This represents a change of -15.67% compared to the average of -0.68 of the last 4 quarters.

Oncternal Therapeutics, Inc. (ONCT) Historical PE Ratio (quarterly & annually)

How has ONCT PE Ratio performed in the past?

The mean historical PE Ratio of Oncternal Therapeutics, Inc. over the last ten years is -39.12. The current -0.57 PE Ratio has changed 45.71% with respect to the historical average. Over the past ten years (40 quarters), ONCT's PE Ratio was at its highest in in the March 2016 quarter at 168.00. The PE Ratio was at its lowest in in the March 2021 quarter at -343.36.

Quarterly (TTM)
Annual

Average

-39.12

Median

-7.63

Minimum

-145.65

Maximum

-0.80

Oncternal Therapeutics, Inc. (ONCT) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Oncternal Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 246.69%

Maximum Annual PE Ratio = -0.80

Minimum Annual Increase = -93.49%

Minimum Annual PE Ratio = -145.65

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.80-34.13%
2022-1.21-66.12%
2021-3.58-38.13%
2020-5.78125.48%
2019-2.56-72.95%
2018-9.48-93.49%
2017-145.6567.91%
2016-86.75-17.44%
2015-105.07246.69%
2014-30.31-38.67%

Oncternal Therapeutics, Inc. (ONCT) Average PE Ratio

How has ONCT PE Ratio performed in the past?

The current PE Ratio of Oncternal Therapeutics, Inc. (ONCT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-1.86

5-year avg

-2.79

10-year avg

-39.12

Oncternal Therapeutics, Inc. (ONCT) PE Ratio vs. Peers

How is ONCT’s PE Ratio compared to its peers?

Oncternal Therapeutics, Inc.’s PE Ratio is less than Neoleukin Therapeutics, Inc. (0), greater than CytomX Therapeutics, Inc. (-0.98), less than Assembly Biosciences, Inc. (6.85), greater than Instil Bio, Inc. (-1.62), greater than Nuvation Bio Inc. (-0.67), greater than Protara Therapeutics, Inc. (-9.54), greater than Vaccinex, Inc. (-0.60), less than Monopar Therapeutics Inc. (-0.49), greater than Miromatrix Medical Inc. (-1.42), greater than Surrozen, Inc. (-3.41), less than Passage Bio, Inc. (-0.50), greater than Absci Corporation (-0.60), greater than Adverum Biotechnologies, Inc. (-3.61), greater than Kezar Life Sciences, Inc. (-1.19), less than Armata Pharmaceuticals, Inc. (-0.45), greater than Pasithea Therapeutics Corp. (-1.36), less than Aditxt, Inc. (-0.37), less than null (-0.06),

Build a custom stock screener for Oncternal Therapeutics, Inc. (ONCT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncternal Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Oncternal Therapeutics, Inc. (ONCT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Oncternal Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Oncternal Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Oncternal Therapeutics, Inc. (ONCT)?

What is the highest PE Ratio for Oncternal Therapeutics, Inc. (ONCT)?

What is the 3-year average PE Ratio for Oncternal Therapeutics, Inc. (ONCT)?

What is the 5-year average PE Ratio for Oncternal Therapeutics, Inc. (ONCT)?

How does the current PE Ratio for Oncternal Therapeutics, Inc. (ONCT) compare to its historical average?